Evidence map›Paper›PMID 26267621›Full record

ArticleThe New England journal of medicine2015

High HLA-DP Expression and Graft-versus-Host Disease.

Effie W Petersdorf, Mari Malkki, Colm O'hUigin, Mary Carrington, Ted Gooley, Michael D Haagenson, Mary M Horowitz, Stephen R Spellman, Tao Wang, Philip Stevenson

Open access · bronzeAbstract read
In one paragraph

Article in The New England journal of medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 140 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
140citing papers in PubMed, 3 pooled it
23.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

140 citing papers in PubMed, 3 syntheses or guidelines pooled it, 271 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

80 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Effie W PetersdorfFrom the Division of Clinical Research, Fred Hutchinson Cancer Research Center (E.W.P., M.M., T.G., P.S.), and the Department of Medicine, University of Washington School of Medicine (E.W.P.) - both in Seattle; Cancer and Inflammation Program, Laboratory of Experimental Immunology, Leidos Biomedical Research, Frederick National Laboratories for Cancer Research, Frederick, MD (C.O., M.C.); Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Boston (M.C.); Center for International Blood and Marrow Transplant Research, Minneapolis (M.D.H., S.R.S.); and Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee (M.M.H., T.W.).
Mari Malkki
Colm O'hUigin
Mary Carrington
Ted Gooley
Michael D Haagenson
Mary M Horowitz
Stephen R Spellman
Tao Wang
Philip Stevenson
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZAFred Hutch Cancer Center · USLeidos (United States) · USMedical College of Wisconsin · US

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Marian Esvelt · 1985 to 2026
$296.4M
VIRUS-MEDIATED MYELOSUPPRESSIONP01CA018029 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Geoffrey Roger HILL · 1985 to 2026
$128.4M
Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
PB vs. BMU01HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2001 to 2010
$63.3M
Hematopopietic Stem Cell TransplantationU01AI069197 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Effie W Petersdorf · 2005 to 2026
$18.9M
Clinical Significance of MHC Haplotypes in Hematopoietic Cell TransplantationR01CA100019 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETERSDORF, EFFIE W · 2003 to 2025
$9.1M
CCR NIH HHS HHSN261200800001CNCI NIH HHS CA100019NCI NIH HHS CA18029NCI NIH HHS CA76518NCI NIH HHS HHSN261200800001ENCI NIH HHS P01 CA018029NCI NIH HHS P30 CA015704NCI NIH HHS R01 CA100019NCI NIH HHS U24 CA076518NCI NIH HHS U24-CA76518NHLBI NIH HHS 5U01HL069294NHLBI NIH HHS U01 HL069294NIAID NIH HHS AI069197NIAID NIH HHS U01 AI069197PHS HHS HHSH234200637015C
6 · The paper itself

Abstract

backgroundTransplantation of hematopoietic cells from unrelated donors can cure blood disorders but carries a significant risk of acute graft-versus-host disease (GVHD). The risk is higher when the recipient and donor are HLA-DPB1-mismatched, but the mechanisms leading to GVHD are unknown. The HLA-DPB1 regulatory region variant rs9277534 is associated with HLA-DPB1 expression. We tested the hypothesis that the GVHD risk correlates with the rs9277534 allele linked to the mismatched HLA-DPB1 in the recipient.

methodsWe genotyped rs9277534 in 3505 persons to define rs9277534-DPB1 haplotypes. Among 1441 recipients of transplants from HLA-A,B,C,DRB1,DQB1-matched unrelated donors with only one HLA-DPB1 mismatch, linkage of the rs9277534 A and G alleles to the mismatched HLA-DPB1 was determined. HLA-DPB1 expression was assessed by means of a quantitative polymerase-chain-reaction assay. The risk of acute GVHD among recipients whose mismatched HLA-DPB1 allele was linked to rs9277534G (high expression) was compared with the risk among recipients whose mismatched HLA-DPB1 allele was linked to rs9277534A (low expression).

resultsThe mean HLA-DPB1 expression was lower with rs9277534A than with rs9277534G. Among recipients of transplants from donors with rs9277534A-linked HLA-DPB1, the risk of acute GVHD was higher for recipients with rs9277534G-linked HLA-DPB1 mismatches than for recipients with rs9277534A-linked HLA-DPB1 mismatches (hazard ratio, 1.54; 95% confidence interval [CI], 1.25 to 1.89; P<0.001), as was the risk of death due to causes other than disease recurrence (hazard ratio, 1.25; 95% CI, 1.00 to 1.57; P=0.05).

conclusionsThe risk of GVHD associated with HLA-DPB1 mismatching was influenced by the HLA-DPB1 rs9277534 expression marker. Among recipients of HLA-DPB1-mismatched transplants from donors with the low-expression allele, recipients with the high-expression allele had a high risk of GVHD. (Funded by the National Institutes of Health and others.).

Indexed as

AdolescentAdultFemaleGenetic LinkageGenotypeGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHistocompatibility TestingHLA-DP beta-ChainsHumansMaleMiddle AgedPolymerase Chain ReactionPolymorphism, Single NucleotideProportional Hazards ModelsRegulatory Sequences, Nucleic AcidHLA-DPB1 antigenHLA-DP beta-Chains

Identifiers

PMID26267621
PMCPMC4560117
OpenAlexW2258080942

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.